出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/02/12 18:04:24」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
  • Min YW1, Rhee PL2.
  • Therapeutic advances in gastroenterology.Therap Adv Gastroenterol.2015 May;8(3):136-42. doi: 10.1177/1756283X15572580.
  • Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT3 receptor antagonists have been reported to slow colon transit,
  • PMID 25949526
  • The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
  • Lewis JH1.
  • Drug safety.Drug Saf.2011 Jul 1;34(7):545-65. doi: 10.2165/11590690-000000000-00000.
  • Ischaemic colitis (IC) is the most common form of ischaemic injury to the gastrointestinal (GI) tract. IC typically presents with the sudden onset of lower abdominal pain, cramping and rectal bleeding, and is usually self-limited with low morbidity, although it may cause gangrenous or fulminant coli
  • PMID 21663331
  • Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
  • Painsipp E1, Shahbazian A, Holzer P.
  • British journal of pharmacology.Br J Pharmacol.2009 Nov;158(5):1210-26. doi: 10.1111/j.1476-5381.2009.00392.x. Epub 2009 Sep 25.
  • BACKGROUND AND PURPOSE: As the use of the 5-HT(3) receptor antagonist alosetron (GlaxoSmithKline) and the 5-HT(4) receptor agonist tegaserod (Novartis) in patients with irritable bowel syndrome has been associated with cases of ischaemic colitis, the effects of alosetron, cilansetron (Solvay) and te
  • PMID 19785647


  • Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome
  • HIRATA Takuya,KETO Yoshihiro,FUNATSU Toshiyuki,AKUZAWA Shinobu,SASAMATA Masao
  • Journal of pharmacological sciences 104(3), 263-273, 2007-07-20
  • … We examined the pharmacological profile of ramosetron, a 5-HTsub3/sub-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HTsub3/sub-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide. … Dissociation of ramosetron from the human 5-HTsub3/sub receptor was extremely slow (tsub1/2/sub = 560 min), while alosetron (tsub1/2/sub = 180 min) and cilansetron (tsub1/2/sub = 88 min) dissociated relatively rapidly. …
  • NAID 10024314859


Developed by Solvay Pharmaceuticals, cilansetron is a 5-HT3 antagonist indicated for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS). With Phase III registration trials on cilansetron completed, Solvay filed for ...
A complete review of Cilansetron. This product is used by IBS sufferers who experience predominant diarrhea. ... Cilansetron Cilansetron - A product that provides relief to IBS patients (men and women) with predominant diarrhea


File:Cilansetron.svg - WikipediaCilansetron - New Treatment for IBSDrug Development Technology Cilansetron Sertraline - The Full Wikicilansetron | Ligand page | IUPHAR/BPS Cilansetron - Wikipedia